Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA | P00813 | 1/20 | 0.40 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.40 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 6/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | DAGLA | Q9Y4D2 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20621502 | 1.00 | ADA (0.40) | ADACYSLTR2CYSLTR1TLR8NOS3 | |
| SCHEMBL19779582 | 0.98 | ADA (0.40) | ADACYSLTR2CYSLTR1TLR8NOS3 | |
| SCHEMBL21142402 | 0.97 | ADA (0.39) | ADACYSLTR2CYSLTR1TLR8NOS3 | |
| SCHEMBL29814520 | 0.94 | ADA (0.39) | ADACYSLTR2CYSLTR1TLR8NOS3 | |
| SCHEMBL11401188 | 0.93 | NOS2 (0.41) | ADACYSLTR2CYSLTR1TLR8NOS3 | |
| SCHEMBL21883628 | 0.90 | NOS2 (0.39) | ADACYSLTR2CYSLTR1TLR8NOS3 | |
| SCHEMBL29814823 | 0.87 | NOS2 (0.39) | ADATLR8NOS3NOS1NOS2 | |
| SCHEMBL21755112 | 0.86 | ADA (0.42) | ADATLR8NOS3NOS1NOS2 | |
| SCHEMBL27834249 | 0.84 | ADA (0.40) | ADATLR8NOS3NOS1NOS2 | |
| SCHEMBL30541526 | 0.84 | ADA (0.40) | ADATLR8NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597377-B2 | Somatostatin modulators and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2020-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597377-B2 | Somatostatin modulators and uses thereof | SSTR5, SSTR2, SSTR4 | ADA 2092/4885CYSLTR2 1359/4885CYSLTR1 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.